Celldex Therapeutics Inc. (CLDX) Now Covered by Brean Capital
Stock analysts at Brean Capital started coverage on shares of Celldex Therapeutics Inc. (NASDAQ:CLDX) in a report issued on Tuesday. The brokerage set a “buy” rating and a $16.00 price target on the biopharmaceutical company’s stock. Brean Capital’s price objective indicates a potential upside of 286.47% from the stock’s current price.
CLDX has been the subject of several other research reports. Cowen and Company reiterated an “outperform” rating and issued a $12.00 price objective on shares of Celldex Therapeutics in a research report on Tuesday, June 7th. Wedbush reiterated a “neutral” rating and issued a $3.00 price objective on shares of Celldex Therapeutics in a research report on Tuesday, August 9th. Finally, Jefferies Group lifted their price objective on Celldex Therapeutics to $5.00 and gave the company a “hold” rating in a research report on Friday, August 5th. Six analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $9.75.
Shares of Celldex Therapeutics (NASDAQ:CLDX) opened at 4.14 on Tuesday. The stock’s 50 day moving average price is $3.75 and its 200 day moving average price is $4.17. The stock’s market capitalization is $416.26 million. Celldex Therapeutics has a one year low of $2.96 and a one year high of $18.62.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/09/celldex-therapeutics-inc-cldx-now-covered-by-brean-capital.html
Celldex Therapeutics (NASDAQ:CLDX) last posted its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.32) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.34) by $0.02. The business earned $1.39 million during the quarter, compared to the consensus estimate of $0.96 million. Celldex Therapeutics had a negative return on equity of 47.59% and a negative net margin of 2,383.60%. Celldex Therapeutics’s revenue was down 36.4% on a year-over-year basis. During the same quarter last year, the company earned ($0.33) EPS. On average, analysts forecast that Celldex Therapeutics will post ($1.34) EPS for the current year.
Large investors have recently made changes to their positions in the company. Veritable L.P. bought a new stake in shares of Celldex Therapeutics during the second quarter worth approximately $132,000. Canada Pension Plan Investment Board boosted its stake in shares of Celldex Therapeutics by 304.5% in the first quarter. Canada Pension Plan Investment Board now owns 44,900 shares of the biopharmaceutical company’s stock worth $170,000 after buying an additional 33,800 shares during the period. Bank of Montreal Can bought a new stake in shares of Celldex Therapeutics during the second quarter worth approximately $188,000. KCG Holdings Inc. boosted its stake in shares of Celldex Therapeutics by 103.5% in the second quarter. KCG Holdings Inc. now owns 54,297 shares of the biopharmaceutical company’s stock worth $238,000 after buying an additional 27,613 shares during the period. Finally, National Planning Corp boosted its stake in shares of Celldex Therapeutics by 3.1% in the second quarter. National Planning Corp now owns 55,246 shares of the biopharmaceutical company’s stock worth $251,000 after buying an additional 1,650 shares during the period. 78.41% of the stock is owned by institutional investors and hedge funds.
About Celldex Therapeutics
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (rindopepimut and CDX-110) is a therapeutic vaccine in clinical studies for the treatment of glioblastoma patients that express a specific cancer marker known as type III epidermal growth factor receptor mutation (EGFRvIII).
Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.